Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Revolution Medicines, Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06445062CT.gov Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rmc-9805 (this asset) | Revolution Medicines, Inc. | P1/2 | CC · 45 |
| Dexasone | Cedars-Sinai Medical Center | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Brian Anderson, MD | P4 | BB |
| Irinotecan | Amgen | P2 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P2 | BB |
| Epinephrine | Cedars-Sinai Medical Center | P4 | BB |
| Marcaine | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | P4 | BB |
| Mlf 541 | B. Braun Melsungen AG | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | B |
+42 more in the Digestive System Cancer cohort
Other indications for Rmc-9805
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | — | P1/2 | CCC · 50 |
| Lung Cancer | — | P1/2 | CCC · 48 |
| Non-Small Cell Lung Carcinoma | — | P1/2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rmc-9805 in Digestive System Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rmc-9805-digestive-system-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →